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Summary
Objective: Both arg-vasopressin (AVP) and parathyroid hormone-related protein (PTHrP) may act as proinﬂammatory hormones. In addition,
they have been suggested to be involved in the pathophysiology of rheumatoid arthritis (RA). We therefore investigated the effects of AVP and
PTHrP (1e34) on cell proliferation and secretion of the glycoprotein YKL-40 in human chondrocytes derived from healthy subjects as well as
from patients with RA or osteoarthritis (OA).
Method: Primary cultures of human chondrocytes were incubated with AVP (1e100 pmol/l) or PTHrP (1e34) (0.1e100 nmol/l). Cell prolifer-
ation was measured as [3H]thymidine incorporation. Intracellular cAMP and YKL-40 in cell medium were determined by commercially available
kits.
Results: AVP and PTHrP (1e34) increased proliferation in chondrocytes derived from healthy donors as well as from RA and OA patients.
PTHrP (1e34), but not AVP, increased intracellular levels of cAMP. PTHrP (1e34) did not change the amount of YKL-40 in chondrocytes
from healthy subjects or patients with OA. AVP tended to decrease the secretion of YKL-40 from healthy chondrocytes. Both PTHrP
(1e34) and AVP increased YKL-40 secretion from RA chondrocytes. In contrast, AVP decreased the secretion of YKL-40 in chondrocytes
from patients with OA.
Conclusion: AVP and PTHrP (1e34) stimulated proliferation in human chondrocytes derived from healthy subjects as well as from patients
with RA or OA. However, the effects of AVP and PTHrP (1e34) on YKL-40 secretion varied depending on the origin of the chondrocytes.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The hypothalamic nonapeptide and neurohypophyseal hor-
mone arg-vasopressin (AVP) also known under the name
antidiuretic hormone is most well-known for its effects on
water reabsorption in the kidney. However, AVP has a lot
of other effects within the body. Production of AVP as well
as expression of AVP receptors have been demonstrated
in many tissues besides the brain and the kidney1,2. AVP
is released, not only in response to hyperosmotic stimuli
and dehydration, but also in response to stress and proin-
ﬂammatory cytokines such as IL-1b, IL-6 and TNF-a3.
AVP potentiates the release of ACTH, and has thereby an
indirect effect on inﬂammation4. In addition, AVP itself has
proinﬂammatory properties. For example, it stimulates anti-
body responses and lymphocyte reactions3,5e7. Preliminary
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Received 3 July 2005; revision accepted 3 January 2006.6studies indicate that plasma levels of AVP are increased in
patients with rheumatoid arthritis (RA)5.
It has previously been shown that lys-vasopressin stimu-
lates proliferation of chondrocytes from mice8, and we have
recently found that AVP stimulates proliferation of human
osteoblast (hOB)-like cells9. To our knowledge the effects
of AVP on proliferation in human chondrocytes have not
been investigated.
Parathyroid hormone-related protein (PTHrP) was dis-
covered 25 years ago as a tumor product causing hypercal-
cemia10e12. It is, in similarity to AVP, produced in many
different tissues in the body13. Interestingly, PTHrP and
AVP modulate each others release within the hypothalamic
supraoptical nucleus14. In contrast to AVP, the effects of
PTHrP on cell proliferation in human chondrocytes
are well-known. PTHrP stimulates proliferation and regu-
lates differentiation of chondrocytes13,15. PTHrP knockout
mice have severe chondrodysplasia and die shortly after
birth16.
PTHrP is produced in increased amounts by the syno-
vium in patients with RA or osteoarthritis (OA)17, and the ex-
pression of PTHrP mRNA is increased in chondrocytes
derived from patients with OA18.52
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is a secretory glycoprotein and is produced by chondro-
cytes, synovial cells, macrophages and neutrophils19. It is
one of the most abundant proteins secreted by cultured
chondrocytes. YKL-40 has been suggested to be involved
in the remodeling or degradation of extracellular matrix
and to be a differentiation marker in chondrocytes19e21.
YKL-40 levels are increased in serum and in chondrocytes
derived from patients with RA and seem to be changed
also in patients with OA22e26. In patients with RA, a positive
correlation between YKL-40 in serum and the degree of
inﬂammation as well as joint destruction has been demon-
strated22,24,27. Therefore, it has been suggested that YKL-
40 may be involved in the pathophysiology of joint disorders
such as RA and OA24,28.
The aim of the present study was to investigate the
effects of AVP and PTHrP on cell proliferation in chondro-
cytes derived from healthy subjects, and from patients
with RA or OA. A second aim was to investigate the effects
of AVP and PTHrP on YKL-40 secretion from these 3
groups of chondrocytes.
Method
CHEMICALS
AVP and isobutylmethylxanthine (IBMX) were obtained
from Sigma (St Louis, MO) and PTHrP (1e34) was obtained
from Peninsula (Belmont, USA). Dulbecco’s modiﬁed Ea-
gle’s medium (DMEM) and Nutrient Mixture F-12 (HAM
F12) with L-glutamine, trypsineethylenediaminetetraacetic
acid (trypsineEDTA), penicillin/streptomycin, collagenase,
dispase and fetal calf serum (FBS) were obtained from
Gibco (Grand Island, NY).
[3H]thymidine (6.70 Ci/mmol) was from NEN (Boston,
MA).
Ultima Gold scintillation liquid was from Packard BioSci-
ence Company (Groningen, Holland).
CARTILAGE SPECIMENS
Human articular cartilage was collected from knee-
surgery patients with RA or OA and healthy subjects. The
cartilage was collected in DMEMeHAM F12 (5:1) supple-
mented with 10% FBS, 50 IU/l penicillin and 50 mg/l
streptomycin.
None of the donors used in this study had any medication
known to inﬂuence bone or cartilage.
CELL CULTURES
Non-calciﬁed cartilage from the superﬁcial area of the
tidemark was dissected and diced into pieces of
0.5e1 mm2, washed 3 times with wash solution: DME-
MeHAM F12 supplemented with gentamycin (50 mg/ml), di-
gested overnight at 37(C in DMEMeHAM F12 containing
collagenase (0.8 mg/ml), dispase (0.16%) and 5% FBS.
The following day, the tissueeenzyme solution was
mixed in a pipet and centrifuged at 900 rpm for 5 min. The
supernatant was removed and the pellet was washed
once with the wash solution mentioned above.
The released cells were plated in a 75 cm2 cell culture
ﬂask in DMEMeHAM F12 supplemented with 10% FBS,
50 IU/l penicillin and 50 mg/l streptomycin.
The cells were maintained in humidiﬁed atmosphere at
5% CO2 and 37(C. The medium was replaced twice
a week.After 13e15 days, the chondrocytes were passaged by
release from the culture ﬂask with trypsineEDTA and plated
for measurements of DNA synthesis (cell proliferation),
YKL-40 secretion and intracellular cAMP.
All cells were from the ﬁrst passage except in the exper-
iments with PTHrP (1e34) in chondrocytes from healthy
subjects. In these experiments both cells from ﬁrst and third
passages were used. The reason for this was lack of mate-
rial from the healthy subjects. Also the third passage cells
were positively stained for collagen type II and alcian blue
as described below.
The studies were approved by the Local Ethical Commit-
tee at the Karolinska Hospital, Stockholm.
CHARACTERIZATION OF CHONDROCYTES/
IMMUNOCYTOCHEMISTRY
Chondrocytes were positively stained by immunocyto-
chemistry using rabbit anti-human collagen type II polyclonal
antibody (Chemicon International), and cytochemically by
alcian blue (1%, pH 1.0) (Sigma) staining proteoglycans
which indicates cartilage.
Chondrocytes were plated with a density of 6000 cells/
well in 4-well chamber slides (Nalge Nunc International)
and kept at 37(C in 5% CO2 and 95% air for 4 days with
medium, DMEMeHAM F12 with 50 IU/l penicillin, 50 mg/l
streptomycin and 10% FBS. The medium was changed ev-
ery other day and replaced with serum free medium con-
taining 0.1% BSA 24 h before experiments. Thereafter,
the medium was removed and the cells were ﬁxed with
4% phosphate buffered formaldehyde solution (Histolab,
Sweden) for 30 min followed by 20% sucrose solution for
another 30 min.
MEASUREMENTS OF CELL PROLIFERATION
DNA synthesis was measured using [3H]thymidine incor-
poration which is widely accepted as an index of cell
proliferation.
The chondrocytes were plated in 12-well plates (20,000
cells per well) in DMEMeHAM F12 containing 10% FBS,
50 IU/l penicillin, and 50 mg/l streptomycin. The medium
was changed every other day and after 4 days cells were
cultivated for 24 h in serum free medium with 0.1% BSA.
Thereafter, they were incubated with AVP (1e100 pmol/l)
or PTHrP (1e34) (0.1e100 nmol/l) and [3H]thymidine
(1 mCi/ml) for 24 h. The cells were rinsed twice with 1 ml
ice cold 0.9% NaCl and then left for 15 min in 5% ice cold
trichloroacetic acid. Precipitated material was extracted
with 0.5 ml of 0.1 mol/l NaOH for 2 h at room temperature
under constant slow shaking. The radioactivity in each
well was measured in a liquid scintillation b-counter after
addition of 4 ml Ultima Gold scintillation liquid.
INTRACELLULAR cAMP
The chondrocytes were plated in 12-well plates (20,000
cells per well) in DMEMeHAM F12 containing 10% FBS,
50 IU/l penicillin, and 50 mg/l streptomycin. After 48 h the
cells were washed twice with, and then cultivated in, serum
free medium with 0.1% BSA. After another 24 h, the cells
were incubated for 60 min with 0.5 mM IBMX and then
with 0.5 mM IBMX containing PTHrP (1e34) 1 nmol/l,
AVP 10 or 100 pmol/l, vehicle or 40 mM forskolin for
10 min. Intracellular cAMP was extracted with 90% propa-
nol for 24 h at 4(C. The propanol solution was centrifuged
for 5 min at 3000 rpm, and after evaporation of the
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later cAMP analysis with the BIOTRAK cAMP radioimmuno-
assay system (Amersham Life Science, Buckinghamshire,
England), detection limit 25 fmol/tube.
SECRETION OF YKL-40
Chondrocytes were plated and incubated with AVP or
PTHrP (1e34) as described above.
The cell medium was collected, centrifuged and the su-
pernatant was frozen and kept at 20(C until measure-
ments of YKL-40 by an EIA kit (METRA, Quidel, USA).
STATISTICAL ANALYSIS
The results are presented as means SD. Statistical
analysis was performed by a Student’s t test or a one-way
analysis of variance (ANOVA) followed by Fisher’s test for
post hoc comparisons. P-values of 0.05 or less were re-
garded as statistically signiﬁcant.
Results
CELL PROLIFERATION
PTHrP (1e34)
PTHrP (1e34) increased cell proliferation in chondrocytes
from healthy subjects (PTHrP 0.1 nmol/l: 128 9.3%,
P< 0.01; 1 nmol/l: 142 17%, P< 0.001; 10 nmol/l:
126 10%, P< 0.01; 100 nmol/l: 124 13%, P< 0.01), pa-
tients with OA (PTHrP 0.1 nmol/l: 151 29%, P< 0.001;
1 nmol/l: 125 18%, P< 0.05) and patients with RA (PTHrP
0.1 nmol/l: 131 34%, P< 0.05; 1 nmol/l: 132 22%,
P< 0.05; 10 nmol/l: 122 8.6%, P¼ 0.057) (Fig. 1).
AVP
AVP increased cell proliferation of chondrocytes from
healthy subjects (AVP 1 pmol/l: 174 49%, P< 0.01;
10 pmol/l: 147 54%, P< 0.05; 100 pmol/l: 187 65%,
P< 0.01), patients with OA (AVP 1 pmol/l: 168 13%,P< 0.001; 10 pmol/l: 128 27%, P¼ 0.058; 100 pmol/l:
155 35%, P< 0.001) and patients with RA (AVP
10 pmol/l: 121 13%, P< 0.01) (Fig. 2).
All data presented are representative of at least 3 sepa-
rate experiments.
FBS (10%)wasusedasapositive control inall experiments.
INTRACELLULAR LEVELS OF cAMP
PTHrP (1e34)
PTHrP (1e34) (1 nmol/l) increased cAMP levels in chon-
drocytes from all groups of subjects (P< 0.001) (Fig. 3).
AVP
No signiﬁcant change in cAMP levels in response to AVP
(10 and 100 pmol/l) was seen (Fig. 4).
All data presented are representative of at least 3 sepa-
rate experiments.
cAMP levels in OA chondrocytes were slightly lower com-
pared to the other 2 groups. This is most likely explained by
the fact that cAMP in these experiments were analysed in
different assays.
Forskolin (40 mM) was used as a positive control and in-
creased cAMP signiﬁcantly.
SECRETION OF YKL-40
PTHrP (1e34)
No effect of PTHrP (1e34) on the secretion of YKL-40 in
chondrocytes derived from healthy subjects or from patients
with OA could be found. PTHrP (1e34) increased the secre-
tion of YKL-40 in chondrocytes derived from patients with
RA (PTHrP 0.1 nmol/l: 131 16%, P< 0.01; 1 nmol/l:
120 11%, P< 0.05; 10 nmol/l: 129 22%, P< 0.01;
100 nmol/l: 140 15%, P< 0.001) (Fig. 5).
AVP
AVP tended to decrease the secretion of YKL-40 in
chondrocytes from healthy subjects (10 pmol: P¼ 0.060
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Fig. 1. Proliferation of human chondrocytes incubated with PTHrP (1e34) 0.1e100 nmol/l for 24 h. The results are expressed as percentage of
the controls and shown as means SD. Statistical evaluation was performed by a one-way ANOVA followed by Fisher’s test for post hoc
comparisons. Healthy e ANOVA: F4,35¼ 10.9, P< 0.001, n¼ 8 for each concentration and control. OA e ANOVA: F4,35¼ 9.40, P< 0.001,
n¼ 8 for each concentration and control. RA e ANOVA: F4,31¼ 3.55, P¼ 0.018, n¼ 6 for each concentration, except the control and PTHrP
(1e34) 1 nmol/l where n¼ 8. *P< 0.05, **P< 0.01, ***P< 0.001, compared to control.
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Fig. 2. Proliferation of human chondrocytes incubated with AVP 1e100 pmol/l for 24 h. The results are expressed as percentage of the con-
trols and shown as means SD. Statistical evaluation was performed by a one-way ANOVA followed by Fisher’s test for post hoc compar-
isons. Healthy e ANOVA: F3,32¼ 6.38, P¼ 0.0016, n¼ 12 for the control and AVP 10 pmol/l, n¼ 6 for AVP 1 and 100 pmol/l. OA e ANOVA:
F3,19¼ 10.2, P< 0.001, n¼ 6 for each concentration and control, except AVP 10 pmol/l where n¼ 5. RA e ANOVA: F3,20¼ 9.57, P< 0.001,
n¼ 6 for each concentration and control. *P< 0.05, **P< 0.01, ***P< 0.001, compared to control.compared to controls), but the ANOVA did not reach signif-
icance (ANOVA F3,20¼ 1.86, P¼ 0.16).
AVP decreased the secretion of YKL-40 in chondrocytes
from patients with OA (AVP 1 pmol/l: 66 5.9%, P< 0.001;
10 pmol/l: 92 4.5%, P¼ 0.065; 100 pmol/l: 93 7.4%,
P¼ 0.059). In contrast, an increase in YKL-40 secretion in
response to AVP 1 pmol/l was found in RA chondrocytes
(121 24%, P< 0.05) (Fig. 6).
All data presented are representative of at least 2 sepa-
rate experiments.
Discussion
The present study showed that AVP and PTHrP (1e34)
increased proliferation of human chondrocytes derived
from healthy subjects as well as from patients with OA
and patients with RA. In addition, AVP and PTHrP (1e34)
inﬂuenced the secretion of YKL-40 from the cultured human
chondrocytes. These effects differed depending on the ori-
gin of the chondrocytes. The production of YKL-40 was not
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Fig. 3. Intracellular cAMP levels in human chondrocytes incubated
with PTHrP (1e34) 1 nmol/l for 10 min. The results are shown as
meansSD. Statistical evaluation was performed by a Student’s
t test; n¼ 6 for each concentration and control, ***P< 0.001, com-
pared to control.inﬂuenced by the addition of PTHrP (1e34) in chondrocytes
from healthy subjects or patients with OA. Addition of AVP
decreased the production of YKL-40 in OA chondrocytes
and tended to decrease YKL-40 in chondrocytes derived
from healthy subjects. In contrast, AVP and PTHrP
(1e34) stimulated YKL-40 production in chondrocytes
from patients with RA.
A stimulatory effect of AVP on human chondrocyte prolif-
eration has not been reported before. However, as men-
tioned in the Introduction, lys-vasopressin has been
demonstrated to increase proliferation in chondrocytes
from mice8. In the present study, AVP (10e100 pmol/l) stim-
ulated human chondrocyte proliferation signiﬁcantly. Previ-
ous studies have demonstrated similar effects of AVP in
these concentrations on the proliferation of hOB cells9.
The increase in chondrocyte proliferation in response to
PTHrP is in line with previous studies12,15. In the present
study, we could also demonstrate these effects of PTHrP
(1e34) in chondrocytes derived from RA patients and OA
patients as well as in chondrocytes from healthy donors.
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Fig. 4. Intracellular cAMP levels in human chondrocytes incubated
with AVP 10 or 100 pmol/l for 10 min. The results are shown as
meansSD. Statistical evaluation was performed by a one-way
ANOVA. Healthy e ANOVA: F2,15 ¼ 2.14, P ¼ 0.15, n ¼ 6 for
each concentration and control. OA e ANOVA: F2,15 ¼ 1.33,
P¼ 0.29, n¼ 6 for each concentration and control. RA e ANOVA:
F2,15¼ 2.14, P¼ 0.15.
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Fig. 5. Secretion of YKL-40 (ng/ml) incubated with PTHrP (1e34) 0.1 or 1e100 nmol/l for 24 h. The results are expressed as percentage of the
controls and shown as means SD. Statistical evaluation was performed by a one-way ANOVA followed by Fisher’s test for post hoc com-
parisons. Basal YKL-40 secretion: healthy subject 328 64 ng/ml, OA: 150 15 ng/ml, RA: 247 18 ng/ml. Healthy e ANOVA: F3,16¼ 1.20,
P¼ 0.35, control n¼ 5, 1 nmol/l n¼ 5, 10 nmol/l n¼ 4, 100 nmol/l n¼ 3. OA e ANOVA: F4,31¼ 0.46, P¼ 0.77, control n¼ 10, 0.1 nmol/l n¼ 4,
1 nmol/l n¼ 10, 10 nmol/l n¼ 6, 100 nmol/l n¼ 6. RA e ANOVA: F4,26¼ 8.35, P< 0.001, control n¼ 8, 0.1 nmol/l n¼ 5, 1 nmol/l n¼ 8,
10 nmol/l n¼ 4, 100 nmol/l n¼ 6. *P< 0.05, **P< 0.01, ***P< 0.001, compared to control.The effects of PTHrP (1e34) and AVP on the proliferation
of chondrocytes from patients with RA seemed to be
weaker compared to the effects in OA chondrocytes and
the chondrocytes derived from healthy subjects. However,
since the magnitude of the increase in cell proliferation dif-
fered a lot between the different donors of cartilage this
might be just a coincidence. The basal (unstimulated)
YKL-40 secretion varied between the different cell donors
as well. In the present paper, cells from 6 different donors
of cartilage were included. Of importance is that the present
results are representative of a series of experiments per-
formed also in chondrocytes from other subjects than those
included in the present paper.The effects of PTHrP on cell proliferation in chondrocytes
have been shown to be mediated through the PTH/PTHrP1-
receptor, which is coupled to cAMP15. This is in accordance
with the present study where we found an increase in intra-
cellular cAMP in response to PTHrP (1e34). In contrast, no
change in cAMP could be found in chondrocytes incubated
with AVP. Therefore, we suggest that the effects of AVP
were mediated through the AVP V1-receptor which is G-pro-
tein coupled to the phospholipase C and the diacylglycerol/
protein kinase C pathway. In support of this, our previous
studies in hOB cells have demonstrated that the effects of
AVP in these cells are mediated through the V1-receptor.
The V1-receptor is widely distributed in the body and our0
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Fig. 6. Secretion of YKL-40 (ng/ml) from human chondrocytes incubated with AVP 1e100 pmol/l for 24 h. The results are expressed as per-
centage of the controls and shown as meansSD. Statistical evaluation was performed by a one-way ANOVA followed by Fisher’s test for
post hoc comparisons. Basal YKL-40 secretion: healthy subject 110 24 ng/ml, OA: 254 19 ng/ml, RA: 22 2.3 ng/ml. Healthy e ANOVA:
F3,20¼ 1.86, P¼ 0.16, n¼ 6 for each concentration and control. OA e ANOVA: F3,20¼ 33.1, P< 0.001, n¼ 6 for each concentration and con-
trol. RA e ANOVA: F3,20¼ 4.67, P¼ 0.012, n¼ 6 for each concentration and control. *P< 0.05, ***P< 0.001, compared to control.
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addition, the V1-receptor (V1a) is found in blood platelets
and lymphocytes, and it is thought that this receptor medi-
ates the effects of AVP on the immune response3,7,29.
Both AVP and PTHrP have proinﬂammatory effects3,5,30.
AVP increases primary antibody responses and promotes
lymphocyte reactions3,5e7. Immunoneutralization of AVP
decreases experimentally induced inﬂammation in rats31.
AVP attenuates fever in both humans and rats and has
the capacity to modify cytokine levels such as IL-6, M-
CSF and g-interferon3,9,32,33. Worth mentioning is also
that V1a-receptor knockout mice have deﬁciencies in
B-lymphocyte receptor signaling34.
PTHrP is increased in response to injections of high con-
centrations of endotoxins to rats and activated T-cells
express PTHrP30,35. PTHrP inﬂuences IL-6 production in
many different tissues, for example, the synovial cells30.
Previous studies indicate that plasma levels of AVP are
increased in patients with RA5. Since AVP is released to-
gether with CRF during stress and illness, the rise in AVP
levels in RA patients could be stress induced. In similarity
to cortisol released in response to CRF/ACTH (and AVP)
during stress and illness (for a review, see for example, Jeff-
eries36), AVP itself could directly take part in the modulation
of the immune response. Indeed, as mentioned above, sev-
eral studies indicate such effects in response to AVP.
In contrast, no changes in the plasma levels of PTHrP
have been found in patients with RA. However, very low
levels of PTHrP are present in the circulation and increased
concentrations have been measured only in patients with
cancer and in women during breastfeeding37,38.
Instead, the effects of PTHrP in the cartilage are probably
exerted by locally produced PTHrP. Previous studies have
suggested that PTHrP contributes to the joint destruction
that occurs in patients with arthritis39. Indeed, PTHrP is pro-
duced in increased amounts by the synovium in patients with
RA and OA17,40. Moreover, the expression of PTHrP mRNA
is increased in chondrocytes derived from patients with OA18.
PTHrP from the synovial tissue and the chondrocytes in-
teracts with several cytokines. As mentioned above PTHrP
increases IL-6 production from the synovial cells. Addition-
ally, TNF-a and IL-1b elevate PTHrP secretion from the
synovial tissue30,40. IL-1b upregulates PTHrP mRNA
expression and increases protein production in hOB cells41.
Interestingly, the anti-inﬂammatory substances dexametha-
sone (a glucocorticoid) and g-interferon decrease PTHrP
production in the synovial cells40.
A rise in YKL-40 levels has been linked to the degree of
inﬂammation and joint destruction in patients with RA. In ad-
dition, YKL-40 has been suggested to be a biochemical
marker for diagnosis as well as prognosis and treatment
of RA22,24,27. In the present study, we did not ﬁnd an in-
crease in YKL-40 secretion from the RA chondrocytes. In
contrast, the lowest amounts of YKL-40 secretion were
found in cells from one of the RA donors.
However, the fact that the present study showed an in-
crease in YKL-40 secretion in response to AVP and PTHrP
(1e34) in chondrocytes derived from patients with RA,
could be in further support of the suggestion of a role for
these hormones in the pathophysiology of RA.
Indeed, other studies have demonstrated that inhibition of
PTHrP decreases joint destruction in experimentally in-
duced arthritis in rats39.
Studies in cartilage derived from patients with OA have
demonstrated both decreases and increases in YKL-40
levels23,24. For example, immunohistochemical studies
have demonstrated increased YKL-40 staining inchondrocytes from patients with OA42. In contrast, a study
in cartilage from late stage OA patients showed decreased
YKL-40 mRNA levels compared to cartilage from healthy
subjects43. In another study, no difference in YKL-40 levels
between OA chondrocytes and healthy chondrocytes could
be found44. In the present study, PTHrP (1e34) did not
change YKL-40 levels in chondrocytes from patients with
OA whereas AVP caused a signiﬁcant decrease. Thus the
effects of AVP on YKL-40 secretion were opposite in RA
and OA chondrocytes. AVP also tended to decrease YKL-
40 secretion in the healthy chondrocytes.
The changes in YKL-40 secretion might have been in-
duced by an interaction between AVP or PTHrP (1e34)
and cytokines. Since YKL-40 has been suggested to be
a differentiation marker in chondrocytes, AVP and PTHrP
(1e34) may not only have increased chondrocyte prolifera-
tion but they may also have inﬂuenced the differentiation of
the chondrocytes19e21.
TGF-b, which is a growth factor stimulating the formation
of new cartilage, reduces YKL-40 levels. A decrease in
YKL-40 production has also been demonstrated in
response to IL-1b which increases cartilage degradation
and decreases production of extracellular matrix25. YKL-
40 itself is increased during conditions with elevated turn-
over of connective tissue, has growth promoting effects,
increases chondrocyte proliferation and the synthesis of
proteoglycans by the chondrocytes45,46. Thus changes in
YKL-40 levels are difﬁcult to interpret and might indicate
both anabolic and catabolic effects depending on situation
and physiological state. Ling and Recklies have suggested
that YKL-40 has a role in limiting catabolic effects of cyto-
kines during inﬂammation47.
The effects of PTHrP in cartilage and bone have been
suggested to be exerted by locally produced PTHrP13,40.
AVP is produced in many different tissues and it is therefore
possible that AVP, in similarity to PTHrP, is synthesized in
the cartilage, and thereby may induce autocrine/paracrine
effects in the cartilage. The effects of AVP, demonstrated
in the present study, were found using concentrations of
AVP close to the physiological plasma levels. AVP in
plasma from healthy subjects is around 1e5 pmol/l, but
rises higher during, for example, dehydration and
stress48,49. In addition, AVP levels have been suggested
to be increased in patients with RA5. Thus AVP in plasma
may reach bone and cartilage to induce effects in these tis-
sues. Since both AVP and PTHrP also have the capacity to
modulate the immune response they might be involved in
the pathophysiology of inﬂammatory joint disorders such
as RA and OA.
In conclusion, AVP and PTHrP (1e34) increased prolifera-
tion in human chondrocytes. AVP and PTHrP (1e34) also
increased the amount of YKL-40 from chondrocytes derived
from patients with RA, whereas AVP decreased the amount
of YKL-40 from chondrocytes originating from patients withOA.
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